Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Beijing Fanzhi Medical Technology

Request full access

Developer of nucleic acid diagnostic instruments, chips and other testing platforms

ChinaFounded 2016Health Tech & Medtech

About Beijing Fanzhi Medical Technology

Beijing Fanzhi Medical Technology Co., Ltd., also known as FireGen Biomedicals, is a global biopharmaceutical company established on June 3, 2016. The company was founded by a team of returning scientists, Chinese Academy of Sciences (CAS) scientists, and clinical experts, including Dr. Song Keqing, who serves as the founder and CEO. His background in precision medicine has guided the firm's focus. Fanzhi Medical has secured significant funding, including a Series D round of over 100 million CNY in September 2023 and a Series D+ round of a similar scale.

The company specializes in developing and providing integrated solutions for disease diagnostics. Its business model revolves around providing comprehensive "sample-in, result-out" solutions, including detection instruments, chips, diagnostic reagents, and internet-based remote diagnosis and treatment products. It has developed core competencies across four key technology areas: nucleic acids, chips, machinery, and software. Product lines include nucleic acid extraction kits, PCR amplification reagents, and diagnostic tools for conditions like respiratory infections and cardiovascular diseases. The firm's offerings are designed to make advanced, rapid diagnostics accessible to a wide range of clients, from primary care institutions and hospitals to communities and households.

Headquartered in Beijing, Fanzhi Medical operates large-scale GMP facilities, R&D centers, and medical laboratories in several Chinese provinces and has a presence in the United States. The company serves a global client base across more than 30 countries, which includes hospitals, pharmaceutical companies, research institutions, and genetic testing companies. It holds over 150 authorized patents and has received regulatory approvals from China's NMPA, the US FDA, and the European Union's CE for dozens of its products.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
1
Dealroom signal
25.7/100
Industry
Health
Sub-industry
Medical Devices
Sector
Infections and Infectious Diseases, Genetics and genomics, Precision Medicine, Health Diagnostics, Diagnosis and Monitoring, medical testing, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B
Investment activity
3 companies, latest Oct 2023
Capital deployed
$2.8M
Preferred round
SEED

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES D✓Equity / VC Aug 2025 $14M $55M Herui Venture Capital ↗
SERIES D✓Equity / VC Sep 2023 $14M $55M Jianchuang Medical Growth Fund · GSR Capital · Zhilai Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Beijing Fanzhi Medical Technology website traffic

Latest recorded traffic for Beijing Fanzhi Medical Technology is 650 monthly website visits, up 109.7% over the last three months. Beijing Fanzhi Medical Technology's team declined 25% over the past year.

Latest monthly visits650 3-month web change+109.7% 1-year team growth-25%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Beijing Fanzhi Medical Technology in its local ecosystem

Live from Dealroom

The Beijing Fanzhi Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later5 investors entered at this stage

  • CAS Investment Management
  • Jianchuang Medical Growth Fund
  • GSR Capital
  • Zhilai Capital
  • Herui Venture Capital
Employees 9 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Beijing Fanzhi Medical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beijing Fanzhi Medical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.